Enliven Therapeutics (ELVN) Competitors $22.47 -0.40 (-1.75%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELVN vs. AXSM, RARE, APLS, BHVN, PBH, RNA, OGN, PTCT, PRGO, and VRNAShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Axsome Therapeutics (AXSM), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Biohaven (BHVN), Prestige Consumer Healthcare (PBH), Avidity Biosciences (RNA), Organon & Co. (OGN), PTC Therapeutics (PTCT), Perrigo (PRGO), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical preparations" industry. Enliven Therapeutics vs. Axsome Therapeutics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Prestige Consumer Healthcare Avidity Biosciences Organon & Co. PTC Therapeutics Perrigo Verona Pharma Enliven Therapeutics (NASDAQ:ELVN) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment. Is ELVN or AXSM more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -91.87%. Enliven Therapeutics' return on equity of -29.46% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% Axsome Therapeutics -91.87%-158.36%-37.46% Do institutionals and insiders hold more shares of ELVN or AXSM? 95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ELVN or AXSM? Enliven Therapeutics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Do analysts recommend ELVN or AXSM? Enliven Therapeutics presently has a consensus price target of $38.25, indicating a potential upside of 70.23%. Axsome Therapeutics has a consensus price target of $125.93, indicating a potential upside of 38.79%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Enliven Therapeutics is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, ELVN or AXSM? Enliven Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.90-11.83Axsome Therapeutics$338.46M12.99-$239.24M-$6.53-13.89 Does the media refer more to ELVN or AXSM? In the previous week, Axsome Therapeutics had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 8 mentions for Axsome Therapeutics and 3 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.13 beat Axsome Therapeutics' score of 1.06 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ELVN or AXSM? Axsome Therapeutics received 435 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 69.10% of users gave Axsome Therapeutics an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes10100.00% Underperform VotesNo VotesAxsome TherapeuticsOutperform Votes44569.10% Underperform Votes19930.90% SummaryEnliven Therapeutics beats Axsome Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-11.8310.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book3.765.094.784.78Net Income-$71.58M$151.83M$120.31M$225.60M7 Day Performance-2.94%-2.14%-1.92%-1.23%1 Month Performance-8.44%-4.56%13.65%0.46%1 Year Performance51.31%8.87%28.34%15.24% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.7826 of 5 stars$22.47-1.7%$38.25+70.2%+73.9%$1.12BN/A-11.8350Positive NewsAXSMAxsome Therapeutics4.7641 of 5 stars$90.080.0%$125.93+39.8%+25.2%$4.37B$270.60M-13.80589Positive NewsRAREUltragenyx Pharmaceutical4.4414 of 5 stars$45.74-0.1%$87.46+91.2%-2.9%$4.22B$434.25M-7.081,276Analyst ForecastNews CoveragePositive NewsAPLSApellis Pharmaceuticals4.5607 of 5 stars$33.79+1.8%$49.94+47.8%-39.0%$4.20B$396.59M-16.35702Analyst DowngradePositive NewsBHVNBiohaven3.8487 of 5 stars$41.49+7.9%$63.00+51.8%-4.6%$4.20B$462.51M-4.11239Analyst ForecastPBHPrestige Consumer Healthcare3.7935 of 5 stars$82.25-0.1%$85.25+3.6%+27.6%$4.06B$1.11B20.02540Analyst UpgradePositive NewsRNAAvidity Biosciences2.1797 of 5 stars$33.54+3.2%$63.60+89.6%+250.4%$4.00B$10.12M-11.28190Analyst ForecastInsider TradeAnalyst RevisionNews CoverageOGNOrganon & Co.4.8039 of 5 stars$14.74-3.7%$21.33+44.7%+7.2%$3.80B$6.26B2.9110,000PTCTPTC Therapeutics3.6564 of 5 stars$47.89+3.3%$54.08+12.9%+62.7%$3.69B$900.66M-8.041,410Analyst DowngradePRGOPerrigo4.9867 of 5 stars$26.79-2.4%$37.00+38.1%-18.0%$3.65B$4.66B-23.469,140Positive NewsVRNAVerona Pharma0.8479 of 5 stars$42.55+2.7%$43.83+3.0%+156.7%$3.46B$460,000.00-22.2730Positive News Related Companies and Tools Related Companies Axsome Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Apellis Pharmaceuticals Competitors Biohaven Competitors Prestige Consumer Healthcare Competitors Avidity Biosciences Competitors Organon & Co. Competitors PTC Therapeutics Competitors Perrigo Competitors Verona Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELVN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
